The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz

Journal article published in 2021 by Sumbul Asif, Evangelia Baxevanidi, Andrew Hill, Willem Daniel Francois Venter, Lee Fairlie, Masebole Masenya, Celicia Serenata, Simiso Sokhela, Nomathemba Chandiwana 

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by